← Leaderboards
Venetia Zachariou
Boston University Medical Campus
$13,931,250
Attributed
$14,600,001
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,600,001 · 11
By mechanism
R01$7,585,662 · 3
P50$2,372,432 · 1
P01$1,860,172 · 1
R21$1,128,411 · 3
U01$709,989 · 1
R56$516,975 · 1
Top collaborators
- Camron D Bryant1 shared
- Hui Feng1 shared
- Stephanie Puig1 shared
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Matthew D Layne$5,684,227
- Robert A Lafyatis$10,905,922
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularGeneticMediatingBrainGenesComplexNeuronsMouse ModelPharmaceutical PreparationsBehaviorFemaleSensoryAffectViral VectorGene ExpressionChromatinPainGenetic TranscriptionPainful NeuropathyChronic PainOpioidProteinsResponseAddiction
Grant awards (40)
Studies on RGS4-Regulated Pathways in Models of Neuropathic Pain$582,615
R01 · FY2025 · NS · contact PI
Training in BioMolecular Pharmacology$426,360
T32 · FY2025 · GM
Studies on RGS4-Regulated Pathways in Models of Neuropathic Pain$658,390
R01 · FY2024 · NS · contact PI
A Female Specific Role of RGSz1 in Modulation of Chronic Pain$457,980
R01 · FY2024 · NS · contact PI
Animal Models Core$102,541
P01 · FY2024 · DA · contact PI
A Reduced Complexity Cross in BALB/c substrains to identify the genetic basis of oxycodone dependence phenotypes$709,989
U01 · FY2023 · DA · contact PI
Cellular Mechanisms of Antidepressant Drug Actions in Neuropathic Pain Models$363,363
R01 · FY2023 · NS · contact PI
Animal Models Core$358,323
P01 · FY2023 · DA · contact PI
Cellular Mechanisms of Antidepressant Drug Actions in Neuropathic Pain Models$413,273
R01 · FY2022 · NS · contact PI
A Female Specific Role of RGSz1 in Modulation of Chronic Pain$365,324
R01 · FY2022 · NS · contact PI
Animal Models Core$358,323
P01 · FY2022 · DA · contact PI
Targeting PDGFRβ to treat peripheral opioid tolerance$201,153
R21 · FY2022 · DA · contact PI
A Female Specific Role of RGSz1 in Modulation of Chronic Pain$175,065
R01 · FY2022 · NS · contact PI
Cellular mechanisms of antidepressant drug actions in neuropathic pain models$120,483
R01 · FY2022 · NS · contact PI
Cellular mechanisms of antidepressant drug actions in neuropathic pain models$75,171
R01 · FY2022 · NS · contact PI
Cellular mechanisms of antidepressant drug actions in neuropathic pain models$5,651
R01 · FY2022 · NS · contact PI
Cellular mechanisms of antidepressant drug actions in neuropathic pain models$625,723
R01 · FY2021 · NS · contact PI
A Female Specific Role of RGSz1 in Modulation of Chronic Pain$506,137
R01 · FY2021 · NS · contact PI
Animal Models Core$471,012
P50 · FY2021 · MH · contact PI
Animal Models Core$332,298
P01 · FY2021 · DA · contact PI
Cellular mechanisms of antidepressant drug actions in neuropathic pain models$32,056
R01 · FY2021 · NS · contact PI
Cellular mechanisms of antidepressant drug actions in neuropathic pain models$530,497
R01 · FY2020 · NS · contact PI
Animal Models Core$471,012
P50 · FY2020 · MH · contact PI
A Female Specific Role of RGSz1 in Modulation of Chronic Pain$432,567
R01 · FY2020 · NS · contact PI
Animal Models Core$358,325
P01 · FY2020 · DA · contact PI
A Female Specific Role of RGSz1 in Modulation of Chronic Pain$516,975
R56 · FY2019 · NS · contact PI
Animal Models Core$471,012
P50 · FY2019 · MH · contact PI
Cellular mechanisms of antidepressant drug actions in neuropathic pain models$387,462
R01 · FY2019 · NS · contact PI
Animal Models Core$350,362
P01 · FY2019 · DA · contact PI
Animal Models Core$471,009
P50 · FY2018 · MH · contact PI
Cellular Mechanisms of Antidepressant Drug Actions in Neuropathic Pain Models$370,781
R01 · FY2018 · NS · contact PI
Targeting HDAC6 for the treatment of neuropathic pain$211,875
R21 · FY2018 · NS · contact PI
Animal Models Core$488,387
P50 · FY2017 · MH · contact PI
Cellular Mechanisms of Antidepressant Drug Actions in Neuropathic Pain Models$370,781
R01 · FY2017 · NS · contact PI
Targeting HDAC6 for the treatment of neuropathic pain$254,250
R21 · FY2017 · NS · contact PI
Cellular Mechanisms of Antidepressant Drug Actions in Neuropathic Pain Models$370,781
R01 · FY2016 · NS · contact PI
HDAC5 in the nucleus accumbens modulates the actions of antidepressant drugs in models of neuropathic pain$209,379
R21 · FY2016 · NS · contact PI
Cellular Mechanisms of Antidepressant Drug Actions in Neuropathic Pain Models$370,781
R01 · FY2015 · NS · contact PI
HDAC5 in the nucleus accumbens modulates the actions of antidepressant drugs in models of neuropathic pain$251,754
R21 · FY2015 · NS · contact PI
Cellular Mechanisms of Antidepressant Drug Actions in Neuropathic Pain Models$370,781
R01 · FY2014 · NS · contact PI